PQ Bypass is a medical device startup pioneering minimally invasive treatments for Peripheral Artery Disease (PAD), specifically targeting the superficial femoral artery (SFA) disease. The company operates in the healthcare sector, focusing on developing advanced technologies such as the TORUS Stent Graft, PQ Snare, and PQ Crossing Device. These innovations are designed by physicians for physicians and their patients, aiming to improve the safety and effectiveness of PAD treatments. PQ Bypass is currently enrolling patients in two major clinical trials: the TORUS 2 IDE Clinical Study and the DETOUR 2 IDE Clinical Study. These trials are multi-center, international investigations evaluating the company's stent graft systems. The business model revolves around the development, clinical testing, and eventual commercialization of these medical devices. Revenue is generated through the sale of these devices to healthcare providers once they receive regulatory approval. The company primarily serves hospitals, clinics, and medical professionals specializing in vascular surgery and interventional cardiology.

Keywords: PAD, SFA disease, stent graft, TORUS, DETOUR, minimally invasive, clinical trials, medical devices, vascular surgery, interventional cardiology.